Biodesix, Inc. BDSX recently announced a new post-market clinical validation study, published in CHEST Pulmonary Journal. The study reaffirms the previously established performance of the BDSX’s ...
LOUISVILLE, Colo., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced a new post-market clinical validation ...
BOULDER, Colo.--(BUSINESS WIRE)-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, ...
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. a leader in lung cancer diagnostics, is extending its blood-based testing portfolio with the release of the Nodify CDT TM test, designed to help ...
The payment amount for the Nodify CDT test as established by the Medicare Administrative Contractor is $649. "Receiving ADLT status is a major milestone for Biodesix and confirms the clinical value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback